Regorafenib-Associated Pancreatic Atrophy and Survival Outcomes in Metastatic Colorectal Cancer
Background/Objectives: Regorafenib is a multikinase inhibitor approved for refractory metastatic colorectal cancer (mCRC). VEGF-pathway inhibition may also cause structural changes in normal organs, including pancreatic volume loss. We evaluated pancreatic volume changes during regorafenib therapy and their association with treatment exposure and clinical outcomes. Methods: We retrospectively analyzed 85 of 115 screened patients with mCRC treated with regorafenib at a single center who had contrast-enhanced CT before treatment and at the first response evaluation. Pancreatic atrophy was defined a priori as a ≥10% volume reduction from baseline. Survival was analyzed with a 12-week landmark approach; for OS, landmark and time-dependent Cox models were added. Results: Median pancreatic volume decreased from 54.22 to 50.00 mL (median paired change −5.8%, 95% CI −9.1 to −4.2; p < 0.001), and atrophy developed in 31 patients (36.5%). Atrophy was associated with longer treatment duration (median 149 vs. 92 days; p = 0.001) and higher disease control (58.6% vs. 17.3%; p < 0.001). The conventional PFS comparison favored the atrophy group (5.26 vs. 3.29 months; p = 0.003) but is confounded by guarantee-time bias. In the 12-week landmark population (n = 65), median PFS was 2.50 vs. 1.28 months (log-rank p = 0.046); however, atrophy was not independently associated with PFS (HR 0.68, 95% CI 0.39–1.20; p = 0.181). Median OS was 11.30 vs. 6.74 months (p = 0.271), and atrophy was not independently associated with OS in conventional (HR 0.99, 95% CI 0.60–1.64), landmark (HR 1.05, 95% CI 0.62–1.76), or time-dependent (HR 1.16, 95% CI 0.69–1.94) models. Conclusions: Regorafenib-associated pancreatic atrophy is a measurable imaging finding linked to longer treatment exposure and concurrent disease control. After accounting for guarantee-time bias, it was not independently associated with PFS or OS and should not be regarded as a prognostic biomarker.
Authors
- Talat Aykut (ORCID: https://orcid.org/0000-0002-9614-0651)
- Bahattin Engin Kaya (ORCID: https://orcid.org/0000-0002-3414-5596)
- Oğuzhan Yıldız (ORCID: https://orcid.org/0000-0002-4057-3108)
- Cengiz Kadıyoran (ORCID: https://orcid.org/0000-0002-7173-3530)
- Mehmet Artaç (ORCID: https://orcid.org/0000-0003-2335-3354)
- Murat Araz (ORCID: https://orcid.org/0000-0002-4632-9501)
- İsmail Beypınar (ORCID: https://orcid.org/0000-0002-0853-4096)
- Melek Karakurt Eryılmaz (ORCID: https://orcid.org/0000-0003-2597-5931)
- Ali Fuat Gürbüz (ORCID: https://orcid.org/0000-0003-1455-471X)
Institutions
- Necmettin Erbakan University (TR)
- Alanya Alaaddin Keykubat Üniversitesi (TR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3390/jcm15228897
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00